Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 20, 2026, 6:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,580 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Liver Cancer Clear all
Active, not recruiting Early Phase 1 Interventional

SBRT + Atezolizumab + Bevacizumab in Resectable HCC

NCT04857684
View directory record Official record
Conditions
Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma
Interventions
Atezolizumab, Bevacizumab, Stereotactic Beam Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jul 20, 2026, 6:40 PM EDT
Not listed Phase 2 Interventional

A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma

NCT00423306
View directory record Official record
Conditions
HEPATOCELLULAR CARCINOMA
Interventions
Darinaparsin
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
6
States / cities
Miami, Florida • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Jul 20, 2026, 6:40 PM EDT
Terminated Phase 1 Interventional

A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC)

NCT05375604
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma (HCC), Gastric Cancer Metastatic to Liver, Colorectal Cancer Metastatic to Liver
Interventions
CDK-004
Drug
Lead sponsor
Codiak BioSciences
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Duarte, California • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Jul 20, 2026, 6:40 PM EDT
Enrolling by invitation No phase listed Observational

International Registry of Congenital Portosystemic Shunt (IRCPSS)

NCT06041906
View directory record Official record
Conditions
Congenital Portosystemic Shunt, CPSS (Congenital Portosystemic Shunt)
Interventions
Shunt Closure
Procedure
Lead sponsor
Prof. Valérie Mc Lin
Other
Eligibility
1 Day and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Jul 20, 2026, 6:40 PM EDT
Recruiting Phase 1Phase 2 Interventional

Tebentafusp-tebn With LDT in Metastatic UM

NCT06626516
View directory record Official record
Conditions
Metastatic Uveal Melanoma
Interventions
Tebentafusp-Tebn, GM-CSF (Sargramostim), BCNU
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 2 Interventional

Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)

NCT04123379
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Hepatocellular Carcinoma
Interventions
Nivolumab, BMS-813160, BMS-986253
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 99 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer

NCT02850536
View directory record Official record
Conditions
Liver Metastases
Interventions
anti-CEA CAR-T cells
Biological
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
2
States / cities
Aurora, Colorado • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Jul 20, 2026, 6:40 PM EDT
Withdrawn Phase 1 Interventional

Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer

NCT01956864
View directory record Official record
Conditions
Cirrhosis, Hepatocellular Carcinoma
Interventions
Vitamin D
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Not applicable Interventional Results available

Perioperative Palliative Care Surrounding Cancer Surgery for Patients & Their Family Members

NCT03611309
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
Surgeon-palliative care team co management, Surgeon team alone management
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Stanford, California • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 1 Interventional

Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab

NCT00941499
View directory record Official record
Conditions
Advanced Cancers
Interventions
HAI Oxaliplatin, 5-FU, Bevacizumab, Cetuximab, Leucovorin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Jul 20, 2026, 6:40 PM EDT
Not yet recruiting Phase 2 Interventional

Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer

NCT07226063
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer
Interventions
Durvalumab, Zanzalintinib
Drug
Lead sponsor
Amit Mahipal
Other
Eligibility
19 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 20, 2026, 6:40 PM EDT
Completed No phase listed Observational

Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer

NCT01706432
View directory record Official record
Conditions
Central Nervous System Metastases, Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma With Predominant Intraductal Component, Invasive Lobular Breast Carcinoma, Invasive Lobular Breast Carcinoma With Predominant in Situ Component, Liver Metastases, Lobular Breast Carcinoma in Situ, Lung Metastases, Male Breast Cancer, Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate, Mucinous Ductal Breast Carcinoma, Papillary Ductal Breast Carcinoma, Recurrent Breast Cancer, Stage IV Breast Cancer, Tubular Ductal Breast Carcinoma, Tumors Metastatic to Brain
Interventions
hyperfractionated radiation therapy, laboratory biomarker analysis, stereotactic radiosurgery
Radiation · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Jul 20, 2026, 6:40 PM EDT
Completed No phase listed Observational

A Study of Changes in Hepatic Function During Radiation Therapy Using Hepatobiliary Single Photon Emission Tomography (SPECT)

NCT01519232
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Liver Irradiation
Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 17, 2015 · Synced Jul 20, 2026, 6:40 PM EDT
Terminated Phase 1 Interventional Results available

Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer

NCT01285102
View directory record Official record
Conditions
Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
irinotecan-eluting beads, hepatic artery embolization
Combination Product · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2021 · Synced Jul 20, 2026, 6:40 PM EDT
Terminated Not applicable Interventional Results available

Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery

NCT02881554
View directory record Official record
Conditions
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Stage IV Liver Cancer, Stage IVA Liver Cancer, Stage IVB Liver Cancer, Vascular Thrombosis
Interventions
Computed Tomography, Single Photon Emission Computed Tomography, Technetium Tc-99m Sulfur Colloid
Procedure · Drug
Lead sponsor
University of Washington
Other
Eligibility
19 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jul 20, 2026, 6:40 PM EDT
Completed No phase listed Observational

Long-term Follow-up of HALT-C Sustained Virological Responders

NCT00825877
View directory record Official record
Conditions
Hepatitis C, Hepatocellular Carcinoma, Ascites, Variceal Hemorrhage, Death
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 20, 2026, 6:40 PM EDT
Completed No phase listed Observational

Microarray Analysis of Gene Expression in Liver Tumors

NCT00373737
View directory record Official record
Conditions
Liver Cancer
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2010 · Synced Jul 20, 2026, 6:40 PM EDT
Terminated Phase 3 Interventional

Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7

NCT04777851
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Regorafenib in combination with pembrolizumab, Loco-regional therapy
Drug · Procedure
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 3 Interventional

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

NCT01804829
View directory record Official record
Conditions
Hepatitis C Infection, Viruses, Hepatocellular Carcinoma, Hepatitis, Viral, Human, Liver Cirrhosis
Interventions
Civacir® 10%
Biological
Lead sponsor
Biotest Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
23
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Increasing Uptake of Evidence-Based Screening Services Through CHW-led Multi-modality Intervention

NCT02970136
View directory record Official record
Conditions
Human Papillomavirus, Human Immunodeficiency Virus, Hepatitis C, ColoRectal Cancer
Interventions
OraQuick Swab, Fecal Immunochemical Test, OraQuick Fingerstick, Standard Screening Tests, HPV Self-Sampling Test, Home Based Screening Tests
Device · Other
Lead sponsor
University of Miami
Other
Eligibility
50 Years to 64 Years
Enrollment
754 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 27, 2021 · Synced Jul 20, 2026, 6:40 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Vanguard Study: Testing a New Way to Screen for Cancer

NCT06995898
View directory record Official record
Conditions
Bladder Carcinoma, Breast Carcinoma, Colorectal Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Liver Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Carcinoma
Interventions
Biospecimen Collection, Device Usage, Electronic Health Record Review, Multi-Cancer Detection Test, Questionnaire Administration
Procedure · Device · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
45 Years to 75 Years
Enrollment
24,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
39
States / cities
Pleasanton, California • Cheyenne Wells, Colorado • Denver, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 20, 2026, 6:40 PM EDT
Withdrawn Not applicable Interventional

Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis

NCT01847495
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Irinotecan, CyberKnife
Drug · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Jul 20, 2026, 6:40 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)

NCT01464593
View directory record Official record
Conditions
Colon Cancer Liver Metastasis
Interventions
Lyso-Thermosensitive Liposomal Doxorubicin, 5% Dextrose Solution, ThermoDox
Drug · Other
Lead sponsor
Imunon
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Los Angeles, California • The Bronx, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 2 Interventional Results available

Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver

NCT00003907
View directory record Official record
Conditions
Liver Cancer, Metastatic Cancer
Interventions
cisplatin, doxorubicin, mitomycin, embolization
Drug · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
37
States / cities
Fort Collins, Colorado • Jacksonville, Florida • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2023 · Synced Jul 20, 2026, 6:40 PM EDT